We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern.
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.
New findings about a fatal form of blood cancer could aid the development of new drugs with significantly less harmful side effects than existing chemotherapy.
Many individuals forced to fight an exceptionally aggressive form of the blood cancer acute myeloid leukemia (AML) don't survive more than five years.
11,000 people are predicted to die from acute myeloid leukemia in 2019, according to the American Cancer Society. The cancer starts in the bone marrow. There, mutated genes fail to prevent blood cells from replicating again and again and again, growing tumors.
Acute erythroid leukemia is a high-risk cancer with a dismal prognosis, uncertain genetic basis and controversy surrounding the diagnosis. That is changing, thanks to research led by St. Jude Children's Research Hospital that appears today in the journal Nature Genetics.
The prognosis for older patients with acute myeloid leukemia is poor: very few achieve remission and for those that don't the option is largely palliative.
Cancer cells consume sugar at a higher rate than healthy cells, but they're also hungry for amino acids, the building blocks of proteins and other biomolecules.
Acute myeloid leukemia is the most common form of acute leukemia. It is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells.
Leukemia promotes premature aging in healthy bone marrow cells - according to new research from the University of East Anglia.